Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial
Archives of Cardiovascular Diseases · 2025
DOI: 10.1016/j.acvd.2025.01.006 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Archives of Cardiovascular Diseases, 2025. Verfasst von Romain Didier und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Inserm UMR 1304 (GETBO), Brest University Hospital, Western Brittany Study Group, 29609 Brest, France. Electronic address: …. Hauptthemen laut MEDLINE: Aspirin, Coronary Artery Disease, Stents, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Antithrombotic management in patients with chronic coronary syndrome and previous stent implantation who require long-term oral anticoagulation is highly challenging in daily practice, especially in those at high residual risk of coronary and vascular events. Dual therapy with oral anticoagulation and aspirin may lead to a higher risk of bleeding, whereas stopping aspirin in high-risk patients with coronary artery disease after percutaneous coronary intervention may lead to recurrent ischaemic events. AIM: To assess the optimal antithrombotic regimen that should be pursued long term (often lifelong) in these patients. METHODS: The AQUATIC study is a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicentre study conducted in patients with chronic coronary syndrome at high risk of ischaemic events (i.e., stent implantation [> 6 months before inclusion] in a context of previous acute coronary syndrome and/or with high-risk features of ischaemic event recurrences) and requiring long-term oral anticoagulation. For superiority, we ensure 80% power at level α=0.05 to detect a 25% reduction in hazard in the experimental group relative to the control group. Overall, 2000 patients will be randomized in a 1:1 ratio to receive either oral anticoagulation and aspirin or oral anticoagulation and placebo. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, stroke, systemic embolism, coronary revascularization and acute limb ischaemia. Major bleeding according to the International Society on Thrombosis and Haemostasis definition is a secondary safety endpoint that will be assessed as a priority. CONCLUSION: The AQUATIC trial will test the efficacy and safety of adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome and previous coronary stenting who are at high residual risk of recurrent ischaemic events and require oral anticoagulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Inserm UMR 1304 (GETBO), Brest University Hospital, Western Brittany Study Group, 29609 Brest, France. Electronic address: romain.didier@gmail.com.
- Heart and Lung Institute, Inserm U1011, Institut Pasteur de Lille, University Hospital of Lille, 59000 Lille, France.
- Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION) Study Group, Inserm UMRS 1166, hôpital Pitié-Salpêtrière, AP-HP, Sorbonne université, 75013 Paris, France.
- Inserm U1148/LVTS, French Alliance for Cardiovascular Trials (FACT), AP-HP, université Paris-Cité, 93017 Bobigny, France.
- Clinical Research Unit, Fernand-Widal Hospital, 75010 Paris, France.
- Department of Internal Medicine and Pneumology, Inserm UMR 1304 (GETBO), CIC Inserm 1412, F-CRIN INNOVTE, université de Bretagne Occidentale, Brest University Hospital, 29609 Brest, France.
Zitieren
APA
Didier, R., Lemesle, G., Montalescot, G., Steg, P. H. G., Vicaut, E., Mottier, D., Bauters, C., Mabo, P., Simon, T., Bouleti, C., Andrieu, S., Angoulvant, D., Vanzetto, G., Kerneis, M., Cayla, G., & Gilard, M. (2025). Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial. Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2025.01.006
Vancouver
Didier R, Lemesle G, Montalescot G, Steg PHG, Vicaut E, Mottier D, et al. Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial. Archives of Cardiovascular Diseases. 2025. doi:10.1016/j.acvd.2025.01.006
BibTeX
@article{Didier2025,
author = {Didier, Romain and Lemesle, Gilles and Montalescot, Gilles and Steg, P H Gabriel and Vicaut, Eric and Mottier, Dominique and Bauters, Christophe and Mabo, Philippe and Simon, Tabassome and Bouleti, Claire and Andrieu, Stephane and Angoulvant, Denis and Vanzetto, Gerald and Kerneis, Mathieu and Cayla, Guillaume and Gilard, Martine},
title = {Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial},
journal = {Archives of Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.acvd.2025.01.006}
}
EUVIMED